Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
137 hedge funds and large institutions have $328M invested in Cymabay Therapeutics in 2019 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 38 reducing their positions, and 15 closing their positions.
12,582% more call options, than puts
Call options by funds: $5.58M | Put options by funds: $44K
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
13% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 38
3% more funds holding
Funds holding: 133 → 137 (+4)
32% less capital invested
Capital invested by funds: $485M → $328M (-$157M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.48M |
| 2 |
JP Morgan Chase
New York
|
+$2.81M |
| 3 |
D.E. Shaw & Co
New York
|
+$2.77M |
| 4 |
Morgan Stanley
New York
|
+$2.53M |
| 5 |
Citigroup
New York
|
+$2.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$15.4M |
| 2 |
PA
Perceptive Advisors
New York
|
-$14.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.47M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$3.39M |
| 5 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$3.09M |
CBAY Hedge Fund Activity: Q3 2019 in Review
137 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2019, worth a combined $328M — down 32% from $485M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CBAY positions and 15 closed out — a net gain of 4 holders — while 43 added to existing stakes and 38 trimmed.
The largest buyer was Millennium Management, adding an estimated $4.48M. The largest seller was Vivo Capital, exiting entirely with an estimated $15.4M sold.
- 137 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2019, up from 133 in Q2 2019.
- Funds reported $328M of Cymabay Therapeutics stock for Q3 2019, down 32% quarter-over-quarter.
- 19 funds opened new Cymabay Therapeutics positions in Q3 2019 and 15 closed out, a net change of +4 holders.
- The largest Cymabay Therapeutics buyer in Q3 2019 was Millennium Management, an estimated $4.48M added.
- The largest Cymabay Therapeutics seller in Q3 2019 was Vivo Capital, an estimated $15.4M sold.
Based on aggregated 13F filings for Q3 2019.